Bluewind Medical wins CE Mark for OAB neuromod device
Neurostim developer Bluewind Medical said today it won CE Mark approval in the European union for its OAB-1000 system designed to treat overactive bladder through wireless neurostimulation.
The OAB-1000 device is a wireless, battery-less neurostimulator that is implanted in a minimally invasive procedure near the tibial nerve in the lower leg. The device stimulates the tibial nerve, which influences urinary function, and is powered by an external power and control unit, according to the company.
“Today, neurostimulators that treat OAB are large, bulky, and require complex and expensive surgery. BlueWind’s impla...
Source: Mass Device - June 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Regulatory/Compliance Urology Bluewind Medical Source Type: news
BlueWind Medical Announces CE-Mark for the First in the World Miniature Wireless Neurostimulator to Treat Overactive Bladder
HERZLIYA, Israel, June 15, 2016 -- (Healthcare Sales & Marketing Network) -- Bluewind Medical, developer of a miniature wireless neurostimulation platform to treat multiple clinical indications, announced today that the company has received CE-Mark for it... Devices, Urology, Neurology, RegulatoryBlueWind Medical, OAB-1000, Overactive Bladder, neurostimulator (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 15, 2016 Category: Pharmaceuticals Source Type: news
Propiverine ER Safe, Effective for Overactive BladderPropiverine ER Safe, Effective for Overactive Bladder
The extended-release formulation of propiverine is 'an effective and well-tolerated treatment option' for patients with symptoms of overactive bladder (OAB), according to a new study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2016 Category: Consumer Health News Tags: Urology News Source Type: news
Tackling bedwetting: 5 tips to manage enuresis
Enuresis, otherwise known as urinary incontinence or bedwetting, is fairly common, often embarrassing and sometimes difficult to talk about. It is estimated about 20 percent of boys and 17 percent of girls, ages 6-to-7 years old have some problem with daytime or nighttime wetting. Still, many kids are reluctant to talk about wetting with parents, friends and teachers. Parents themselves often have a hard time confronting the issue.
The Voiding Improvement Program (VIP) at Boston Children’s Hospital uses a comprehensive and patient-tailored approach to help children with incontinence and other urological issues such as ...
Source: Thrive, Children's Hospital Boston - June 7, 2016 Category: Pediatrics Authors: Maureen McCarthy Tags: Health & Wellness bedwetting Dr. Carlos Estrada enuresis Voiding Improvement Program Source Type: news
MassDevice.com +5 | The top 5 medtech stories for June 6, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Axonics wins CE Mark for SNM, touts cost-efficacy study
Axonics Modulation Technologies said today it won CE Mark approval in the European Union for its SNM sacral nerve modulation system and announced the publication of a cost...
Source: Mass Device - June 6, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Axonics wins CE Mark for SNM, touts cost-efficacy study
Axonics Modulation Technologies said today it won CE Mark approval in the European Union for its SNM sacral nerve modulation system and announced the publication of a cost-efficacy study of the device in Neurourology and Urodynamics.
The SNM rechargeable neuromod system is designed to treat overactive bladder, urinary retention and fecal incontinence through sacral nerve stimulation, the Irvine, Calif.-based company said.
The company did not announce plans for commercialization of the device in the region, but said it is preparing to launch a 65-patient post-market clinical follow up study.
“Axonics has successfully...
Source: Mass Device - June 6, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Regulatory/Compliance Urology Axonics Modulation Technologies Source Type: news
Botulinum Toxin Beats Neuromodulation for Overactive BladderBotulinum Toxin Beats Neuromodulation for Overactive Bladder
Onabotulinum toxin A injection appears to be more effective than sacral neuromodulation for urinary incontinence, but comes with more adverse effects, including urinary tract infection. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 11, 2016 Category: Consumer Health News Tags: Urology News Source Type: news
Less is more: Second opinion spares Sam from risky invasive surgery
Like many moms, Brenda Jackson worried about the transition to middle school for her son Sam. He had had mysterious wetting accidents ever since potty training. Doctors had diagnosed an overactive bladder and tried everything — behavioral interventions, medications and dietary changes.
Nothing worked. Fortunately, Sam attended a small Montessori school where all the kids knew and accepted each other.
But as he was getting ready for fifth grade, the specter of middle school, and the teasing that comes with early adolescence, loomed. “That’s a new ball game,” says his Brenda. “We knew we had to take care of thi...
Source: Thrive, Children's Hospital Boston - April 21, 2016 Category: Pediatrics Authors: Nancy Fliesler Tags: Our Patients’ Stories bedwetting Dr. Mark Proctor Dr. Samuel Nurko Dr. Stuart Bauer online second opinion tethered cord Tethered Cord Program Source Type: news
Medtronic Launches Minimally Invasive Overactive Bladder Treatment
Medtronic has launched NURO, a minimally invasive neuromodulation system to treat overactive bladder syndrome (OAB) in patients with urinary urgency, frequency, and urge incontinence. Research has shown that percutaneous tibial neuromodulation (PTNM) — when performed periodically in a urologist’s office — can reduce these symptoms with fewer side effects than medication. (Source: Medical Design Online News)
Source: Medical Design Online News - March 31, 2016 Category: Medical Equipment Source Type: news
Medtronic launches Nuro overactive bladder treatment
Medtronic (NYSE:MDT) said today it launched its Nuro system designed for treating overactive bladder with symptoms of urinary urgency, urinary frequency and urge incontinence.
The Fridley, Minn.-based company said the device is designed to deliver percutaneous tibial neuromodulation treatment, a minimally invasive office-based procedure which provides a “measurable reduction” in urinary frequency or urinary incontinence.
“Many people with OAB are unsatisfied with current treatments and a significant number are not seeking treatment altogether. With the Nuro System, I can offer patients another option ...
Source: Mass Device - March 30, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Urology Medtronic Source Type: news
4 Expert-Backed Truths About How Much Pee Is Too Much
Maybe you're always begging for bathroom breaks on car trips. Maybe you wake up to tinkle twice every night. Maybe you're just worried about the sheer amount of pee that flows from your body. Should you be concerned? Not likely, according to the experts. Yes, too frequent urination, in combination with other symptoms, can be a sign of a medical problem. But there's such a wide variance of acceptable urination levels, chances are you fall well within the norm. The average human pees six or seven times per day, but Dr. Sven Wenske, a urologist with the Columbia University Medical Center, is wary of tell...
Source: Science - The Huffington Post - March 22, 2016 Category: Science Source Type: news
Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women
JNP-0101 on Track for 2016 Investigational New Drug ("IND") Filing
BOSTON, March 21, 2016 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (JNP) ("Juniper" or the "Company"), a women's health ther... Biopharmaceuticals, Urology, Drug Delivery, FDAJuniper Pharmaceuticals, oxybutynin, intra-vaginal, overactive bladder (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2016 Category: Pharmaceuticals Source Type: news
Cranberry Juice Won't Get Rid Of Your UTI
In this study, they took the cranberry itself and put it in a capsule -- the equivalence of drinking 16 ounces of cranberry juice," Boone said. "As you can see, it takes a large amount of pure cranberry to prevent an infection." UTIs account for an estimated 8.1 million visits to health care professionals each year and are the second most common type of infection in the body. The majority of those affected are women, who have more than a 50 percent risk of infection over their lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases. The infection can be caused by several different...
Source: Healthy Living - The Huffington Post - February 12, 2016 Category: Consumer Health News Source Type: news
Cranberry Juice Won't Get Rid Of Your UTI
In this study, they took the cranberry itself and put it in a capsule -- the equivalence of drinking 16 ounces of cranberry juice," Boone said. "As you can see, it takes a large amount of pure cranberry to prevent an infection." UTIs account for an estimated 8.1 million visits to health care professionals each year and are the second most common type of infection in the body. The majority of those affected are women, who have more than a 50 percent risk of infection over their lifetime, according to the National Institute of Diabetes and Digestive and Kidney Diseases. The infection can be caused by several different...
Source: Science - The Huffington Post - February 12, 2016 Category: Science Source Type: news
Axonics pulls in $39m Series B for neurmod bladder control device
Axonics Modulation Technologies said today it raised $38.5 million in a Series B financing round for its sacral neurmodulation technology.
Irvine, Calif.-based Axonics is developing a miniaturized rechargeable neuromod stimulator to treat overactive bladder, urinary retention and fecal incontinence.
Proceeds from the round will go towards a clinical study of its neurmod device in treating overactive bladder patients, slated to begin enrollment in early 2016 in Europe and North America.
“We appreciate that this group of world-class investors recognizes the quality work done by Axonics to create a state-of-the-art rech...
Source: Mass Device - December 21, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Business/Financial News Axonics Modulation Technologies Source Type: news
